Form 4 for EW Edwards Lifesciences
Accepted 2025-01-16 00:00:00 ET · period of report 2025-01-16 · accession 0001225208-25-000685 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-01-16 | 2025-01-16 | EW | Lippis Daniel J. | CVP, JAPAC | S - Sale+OE | $68.76 | -500 | 23.2K | -2% | -$34.4K |
| D | 2025-01-16 | 2025-01-16 | EW | Lippis Daniel J. | CVP, JAPAC | M - OptEx | $45.28 | +500 | 23.7K | +2% | +$22.6K |
| D | 2025-01-16 | 2025-01-16 | EW | Lippis Daniel J. | CVP, JAPAC | M - OptEx | $0.00 | -500 | 1,530 | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-01-16 | S | D | 500 | $68.76 | 23,189.07 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $68.42 to $69.07. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| 2 | Common | Common Stock | 2025-01-16 | M | A | 500 | $45.28 | 23,689.07 | D | — | — | |
| 3 | Derivative | Employee Stock Option (Right to Acquire) | 2025-01-16 | M | D | 500 | $0.00 | 1,530 | D | $45.28 · 2019-05-17 to 2025-05-16 | 500 Common Stock |